Therapeutic Implications of microRNAs in Depressive Disorders: A Review.

MicroRNAs are hidden players in complex psychophysical phenomena such as depression and anxiety related disorders though the activation and deactivation of multiple proteins in signaling cascades. Depression is classified as a mood disorder and described as feelings of sadness, loss, or anger that interfere with a person's everyday activities. In this review, we have focused on exploration of the significant role of miRNAs in depression by affecting associated target proteins (cellular and synaptic) and their signaling pathways which can be controlled by the attachment of miRNAs at transcriptional and translational levels. Moreover, miRNAs have potential role as biomarkers and may help to cure depression through involvement and interactions with multiple pharmacological and physiological therapies. Taken together, miRNAs might be considered as promising novel therapy targets themselves and may interfere with currently available antidepressant treatments.

Intraperitoneal injections of copper ferrite nanoparticles disturb blood, plasma, and antioxidant parameters of Wistar rats in a sex-specific manner.

The present study was designed to report the synthesis and characterization of copper ferrite nanoparticles (CF NPs) and their biocompatibility in Wistar rats. Coprecipitation method was used to generate CF NPs having average diameter of 14.06 nm. NPs were characterized by scanning electron microscopy and X-ray diffraction. Six-week-old Wistar rats of both sexes intraperitoneally received 10 mg/ml saline/Kg body weight of CF NPs for 14 days. Control groups were maintained in parallel that received saline solution for 14 days through same route. Open field and novel object recognition tests, complete blood count, selected plasma parameters, antioxidants, and copper concentration in vital organs were determined in all treatments. Female rats treated with CF NPs had significantly higher platelet count (P = 0.05) and platelet crit (P = 0.05) and decreased plasma triglyceride concentration levels (P = 0.02) than control group. Female rats had significantly increased levels of superoxide dismutase (P = 0.01), catalase (P = 0.05), and malonaldehyde (P = 0.05) in the kidney, while male rats had significantly elevated levels of superoxide dismutase in the lungs (P = 0.01) as compared with respective control groups. Copper concentrations in the liver were significantly higher in both female (P = 0.04) and male (P = 0.05) rats exposed to CF NPs than control group. All other studied parameters of behavioral tests, blood biochemistry, antioxidant, and copper concentrations in the brain varied nonsignificantly (P > 0.05) when compared between CF NPs treated and untreated rats of both sexes. Intraperitoneal supplementation of CF NPs for 14 days disturbed the platelet count, plasma triglyceride concentration, copper levels in the liver, and antioxidant concentrations in the kidney of female Wistar rats. These parameters remained unaffected in male subjects.